
In January 2021, Edison Oncology entered into a licensing agreement with Apollomics, granting them exclusive rights (excluding China, Hong Kong, and Taiwan) for the development and commercialization of EO1001. EO1001 is a novel protein tyrosine kinase inhibitor (TKI) that irreversibly inhibits EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) as a single agent.
Under the terms of the agreement, Edison Oncology received an upfront cash payment and is eligible for future development and sales milestone payments, as well as tiered royalties based on net sales. Apollomics is responsible for all development, regulatory, and commercialization activities in the licensed territories.
About Apollomics, Inc.
Apollomics is an innovative biopharmaceutical company dedicated to developing mono- and combination oncology therapies that harness the immune system and target key molecular pathways to combat cancer. Its pipeline includes development-stage assets such as humanized monoclonal antibodies and targeted therapies aimed at disrupting uncontrolled cancer cell signaling.
For more information, please visit http://www.apollomicsinc.com.
Apollomics USA is headquartered in Foster City, CA.
Transfer of DNA-Damage Response Inhibitor Rights to Rakovina Therapeutics
In March 2021, Edison Oncology transferred rights to three series of novel DNA-damage response (DDR) inhibitors, including the EO2000 series of PARP inhibitors, to Rakovina Therapeutics, Inc. (TSX-V: RKV). Edison Oncology currently holds approximately 34% of Rakovina Therapeutics’ issued and outstanding common shares.
Rakovina Therapeutics focuses on developing innovative cancer treatments based on novel DDR technologies. The company has built a pipeline of DDR inhibitors with the goal of advancing drug candidates into human clinical trials and securing marketing approval from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies.
For more information, please visit Rakovina Therapeutics.
Rakovina Therapeutics is headquartered in Vancouver, Canada.
Business Development Opportunities
Please contact us if you are interested in business opportunities.
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.